Endo Pharmaceuticals Announces Update on Phase III-Program for Orexo AB's Pain Product Rapinyl(TM)
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: On November 1 2007, Orexo´s (STO:ORX) licensing partner Endo Pharmaceuticals has, in connection with the announcement of their Interim Report, left the following information: